Imaging for early stage breast cancer

• Level of evidence 1A for clinical utility of MammaPrint® in the clinical – high group • C-High/g-Low (48% N+ !) show a 5-yr DMFS >94% (with or without CT)

• In the whole population: 14% reduction in CT prescription • In the c-High subgroup: 46% reduction in CT prescription

Cardoso F et al. N Engl J Med 2016; 375:717-729